Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why new TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Our Pipeline
    • Developing New Regimens
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials
Clinical Development

Discovery

TB Alliance manages the largest pipeline of new TB drugs in history. Projects with the potential to have the greatest impact on the disease, while being cost-effective and simple to administer, are prioritized.

Lead Identification

  • Malate Synthetase InhibitorsTexas A&M University
  • PantothenamideTropIQ, Weill Cornel Medical
  • GHIT Hit-to-Lead ProgramsTakeda Pharmaceuticals, Daiichi Sankyo RD Novare
  • GHIT Hit Identification ProgramsAstellas, Fujifilm
  • Clp Lead Identification ProgramsUniversity of Illinois at Chicago, Harvard University, Center of Excellence in Translational Research (CETR)
  • PknBSchrodinger, University of Auckland
  • Whole Cell Hit-to-Lead ProgramGlaxoSmithKline
  • RNA Polymerase InhibitorsCenter of Excellence in Translational Research (CETR)

Lead Optimization

  • Anti-TB Natural ProductsEvotec
  • Intracellular Active SeriesGlaxoSmithKline
  • KasAGlaxoSmithKline
  • MmpL3 InhibitorsAbbVie, ERA4TB
  • InhA InhibitorsGlobal Health Drug Discovery Institute

Preclinical Development

  • Preclinical TB Regimen DevelopmentJohns Hopkins University
  • TBAJ-587 / DiarylquinolineERA4TB
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why new TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)
With Progress against TB in Jeopardy, New and Improved Tools Are More Urgent than Ever
One Year Since U.S. Approval, Accelerating Access to New TB Therapy

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2020 The TB Alliance. All Rights Reserved. Site by Darby Communications